Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Su
Posted Feb 28 2010 4:00pm
Description of Invention: The technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of the exogenous gene into an intergenic region (IGR) of the viral genome (i.e. Modified Vaccinia Ankara, MVA), where the IGR is flanked by open reading frames of conserved poxvirus genes. Furthermore, the invention relates to plasmids vectors useful to insert the exogenous DNA into the genome of a vaccinia virus. Stability can be further enhanced by incorporating silent mutations that decrease the lengths of homopolynucleotide runs in the foreign gene.
Efficient production of vaccinia-vectored vaccines for infectious diseases and other diseases such as cancer
Efficient production of therapeutic proteins from vaccinia-vectored exogenous genes
Enhancing stability of foreign genes in vaccinia-vectored constructs
Increasing efficiency of vaccine production and gene expression
Development Status: The invention is fully developed.
Related Technologies: US, Application No. 12/377,847 filed 17 Feb 2009, Reference No. E-248-2006/0 US, Patent No. 7,045,313, Issued 16 May 2006, Reference No. E-552-1982/2 US, Patent No. 7,015,024, Issued 21 Mar 2006, Reference No. E-552-1982/2 US, Patent No. 6,998,252, Issued 14 Feb 2006, Reference No. E-552-1982/2 US, Patent No. 7,045,136, Issued 16 May 2006, Reference No. E-552-1982/2 US, Application No. 60/840,093 filed 25 Aug 2006, Reference No. E-248-2006/0 PCT, Application No. PCT/IB2007/004575 filed 24 Aug 2007, Reference No. E-248-2006/0 PCT, Application No. PCT/US83/01863 filed 28 Nov 1983, Reference No. E-552-1982/2
LS Wyatt, PL Earl, W Xiao, J Americo, C Cotter, J Vogt, B Moss. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selections. J Virol. 2009 Jul;83(14):7176-7184. [ PubMed: 19420086 ]
Licensing Status: Available for licensing.
Portfolios: Gene Based Therapies Gene Based Therapies - Therapeutics
For Additional Information Please Contact: John Stansberry Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5236 Fax: 301-402-0220